Outcomes of universal access to antiretroviral therapy (ART) in Georgia

Tengiz Tsertsvadze, Nikoloz Chkhartishvili, Lali Sharvadze, Natia Dvali, Otar Chokoshvili, Pati Gabunia, Akaki Abutidze, Kenrad Nelson, Jack Dehovitz, Carlos Del Rio

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76% were men, 60% were injection drug users (IDU), 59% had a history of an AIDS-defining illness, and 53% were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm3. During followup, 152 (20%) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm3 and 86% of patients had viral load <400 copies/ml at the last clinical visit. The Georgia ART program has been successful in treating injection drug users infected with HIV.

Original languageEnglish (US)
Article number621078
JournalAIDS Research and Treatment
StatePublished - 2011
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Outcomes of universal access to antiretroviral therapy (ART) in Georgia'. Together they form a unique fingerprint.

Cite this